SynthesisBlood purification2022
Survival Outcomes of Hemoperfusion and Hemodialysis versus Hemodialysis in Patients with End-Stage Renal Disease: A Systematic Review and Meta-Analysis.
Synthesis in Blood purification, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 28 citations in OpenAlex.
- Hemoadsorption combined with hemodialysis versus hemodialysis alone on mortality in end-stage kidney disease: a randomized, open-label, multicenter trial.Nature communications · 2026Trial
- Enhanced cognitive outcomes with triple-mode dialysis in kidney failure: role of protein-bound toxin clearance.Renal failure · 2025Trial
- Trial
- Revisiting the hemodiafiltration with endogenous reinfusion: what is its merit in clinical practice? A narrative review.Annals of medicine · 2026Review
- Effect of hemoperfusion plus hemodialysis on uremic toxins and anemia in patients with maintenance hemodialysis.Renal failure · 2026Article
- Article
- Comparison of 2-hour versus 4-hour hemoadsorption combined with hemodialysis (HAHD): an in vitro and prospective clinical evaluation.Renal failure · 2025Article
- Article
- Functional Carbon-Based Materials for Blood Purification: Recent Advances Toward Improved Treatment of Renal Failure and Patient Quality of Life.Bioengineering (Basel, Switzerland) · 2025Review
- Efficacy of extracorporeal immunoadsorption therapy for removal of HBsAg.BMC gastroenterology · 2025Article
- Effect of hybrid blood purification on nutritional status, inflammation, and cardiovascular events in patients with end-stage renal disease.Pakistan journal of medical sciences · 2025Article
- Treatment outcomes and determinants of combined hemodialysis-hemoperfusion therapy in chronic glomerulonephritis.American journal of translational research · 2025Article
- Correlation analysis between left ventricular global longitudinal strain and major adverse cardiovascular event occurrence in patients with end-stage renal disease.International urology and nephrology · 2024Article
- Blood purification therapy in chronic renal failure and its impact on renal index, serological index, and inflammatory factors.Annals of medicine and surgery (2012) · 2024Article
- Current Trends in Hemoadsorption Treatment for Critically Ill Patients: are We Moving Forward?Balkan medical journal · 2024Article
- Chorea in Hemodialysis Patients: Report of Two Cases.International journal of nephrology and renovascular disease · 2024Article
- Expanding the potential therapeutic options of hemoperfusion in the era of improved sorbent biocompatibility.Kidney research and clinical practice · 2023Article
- Additional hemoperfusion for patients receiving maintenance hemodialysis: a retrospective analysis.American journal of translational research · 2023Article
- The Revival of Sorbents in Chronic Dialysis Treatment.Seminars in dialysisReview
- The Clinical Efficacy Evaluation of the KHA-200 Hemoperfusion Device in the Treatment of End-Stage Renal Disease Patients Undergoing Blood Purification Therapy.Kidney diseases (Basel, Switzerland)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe maintenance treatment of ESRD puts a great burden on individual patients, society, and the country of China as a whole. Hemoperfusion plus hemodialysis (HP + HD) in ESRD patients can yield modified outcomes such as prolonged life expectancy and improved dialysis quality and quality of life. This study aimed to systematically analyze the effect of HP + HD on the overall survival (OS) rates of ESRD patients and to provide support for clinical decision-making.
methodsA computerized search was performed in the PubMed, Embase, Cochrane Library, CNKI, WanFang Data and SinoMed databases for relevant original research articles. Studies were included or excluded based on their compliance with predefined selection criteria.
resultsTwelve studies were included in the qualitative synthesis and quantitative synthesis (meta-analysis). The meta-analysis showed that the 1-year OS rate (odds ratio [OR]: 3.35, 95% CI: 1.89, 5.91, p < 0.05), 2-year OS rate (OR: 2.88, 95% CI: 1.84, 4.53, p < 0.05), and 5-year OS rate (χ2 = 4.3092, p < 0.05) of patients with ESRD treated with HP + HD were better than those treated with HD, but there was no significant difference in 3-year OS rate (OR: 1.97, 95% CI: 0.76, 5.06, p > 0.05). Subgroup analysis showed the same outcomes in different study designs (1-year OS rate: randomized controlled trials [RCTs]: OR: 4.38, 95% CI: 1.61, 11.88, p < 0.05; cohort studies: OR: 2.90, 95% CI: 1.44, 5.85, p < 0.05; 2-year OS rate: RCTs: OR: 2.99, 95% CI: 1.84, 4.84, p < 0.05) and different age-groups (1-year OS rate: 45-50 years: OR: 3.19, 95% CI: 1.55, 6.57, p < 0.05; 55-60 years: OR: 3.37, 95% CI: 1.07, 10.61, p < 0.05; 2-year OS rate: 50-55 years: OR: 2.86, 95% CI: 1.59, 5.16, p < 0.05: 60-65 years: OR: 4.41, 95% CI: 1.19, 16.30, p < 0.05).
conclusionsThis meta-analysis suggests that the OS rates of ESRD patients treated with HP + HD were better than those of patients treated with HD. A speculative hypothesis for why this is the case may be that HP + HD can achieve the complementary elimination of metabolites, effectively preventing and treating complications caused by long-term dialysis and prolonging life expectancy. Therefore, HP + HD should be widely used in ESRD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.